Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 817 results for "Treatment For Multiple Sclerosis"

Forward Strides For Forward Pharma At Its IPO

Summary FWP, a Danish biopharmaceutical firm focused on treatments for multiple sclerosis (MS), plans have its IPO this week. FWP will offer 9,523,810 shares at an expected price range of $20 to $22; lead underwriters are Jeffries LLC, Leerink ... Seeking Alpha, 5 days ago
IPO Preview: Forward Pharma A/S Seeking Alpha, 5 days ago
IPO Report: Forward Pharma A/S (FWP), 6 days ago
Sexual Development

Multiple Sclerosis Multiple sclerosis (MS) affects an estimated 300,000 to 400,000 individuals in the United States and over two million worldwide. Although it is considered a relatively rare disease, MS is of particular interest recently due to new and e

Although there is no cure for multiple sclerosis (MS), there are many effective ways of managing the disease. Treating MS primarily focuses on developing strategies to manage symptoms. Because symptoms range greatly from patient to patient, it is ... week ago Big change for Multiple Sclerosis sufferers (Newstalk ZB)  Yahoo!Xtra1 week ago Multidisciplinary Management of Multiple Sclerosis Symptoms  Sexual Development1 week ago Clinical Case Reviews and Poster Sessions in Multiple Sclerosis Spasticity: Main Outcomes and Highlights  Sexual Development1 week ago
Med India

Two Major Advances in Multiple Sclerosis

This is Dr Andrew Wilner, reporting for Medscape from MSBoston 2014, the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)/European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting, in Boston, ...
 General Medicine eJournal5 days ago Major step forward for multiple sclerosis treatment in New Zealand  Pharma Letter1 week ago More MS sufferers to get funded treatment (NZ Newswire)  Yahoo!Xtra1 week ago Funding for MS treatments approved  Radio New Zealand1 week ago

Digital PR Awards: Digital Marketing Campaign ($500K +)

Winner: FCB Health - HEY MS, Take This! For decades, people living with multiple sclerosis (MS) had only injections available to treat their condition. In 2010, Novartis' GILENYA became the first oral treatment indicated for people with ...
 PRandMarketingnetwork1 week ago New guidance for treatment of MS  Yahoo! UK and Ireland1 week ago New NHS guidance promises better care for tens of thousands of people with multiple sclerosis  NICE1 week ago
ONE News

Ground breaking deal provides new access for treatments

Ground breaking deal provides new access for thousands of New Zealanders to medical treatments Multiple sclerosis (MS), chronic obstructive pulmonary disease (COPD), chronic myeloid leukaemia (CML) asthma, cystic fibrosis, Parkinson's and ...
 Scoop1 week ago New treatment options for thousands of Kiwis  ONE News1 week ago Deal provides NZers with new access to medical treatments (Fuseworks)  Yahoo!Xtra1 week ago

Evotec announces three research projects for treatment of multiple sclerosis

Evotec AG, a drug discovery and development company, has entered into three novel research projects for the treatment of multiple sclerosis, or MS, supported by research funds from the German Federal Ministry of Education and Research, or BMBF. The ...
 Individual.com2 weeks ago Evotec partners to develop multiple sclerosis treatments  Center Watch2 weeks ago
Bioresearch Online

Glialogix and National Multiple Sclerosis Society Enter Into Collaboration to Support Development of a New Oral Therapy for Progressive Multiple...

Glialogix and National Multiple Sclerosis Society Enter Into Collaboration to Support Development of a New Oral Therapy for Progressive Multiple Sclerosis By a News Reporter-Staff News Editor at Clinical Trials Week Glialogix, Inc, a San ...
 Pharmacy Choice1 week ago Glialogix Receives National Multiple Sclerosis Society Funding For Treatment Development  Bioresearch Online2 weeks ago Glialogix, National Multiple Sclerosis Society collaborate  Center Watch2 weeks ago

Multiple Sclerosis (MS) Drugs and Biologics : Technologies and Global Markets 2014

LONDON, Oct. 14, 2014 /PRNewswire/ -- This BCC Research study offers an overview of the multiple sclerosis (MS) disease-modifying product market, including regulatory issues accompanied by detailed analyses and forecasts by product. Its main ...
 TickerTech.com6 days ago EU regulator warns on possible MS drugs side effects  Reuters2 months ago
Securities Technology Monitor

Natural Multiple Sclerosis Treatment Review Exposes New eBook Featuring Natural Cures for MS

Denver, CO -- (SBWIRE) -- 10/13/2014 -- The Natural Multiple Sclerosis Treatment program is fully presented in Dr. Gary M. Levin's guide. Reviewed by, this new guide reveals some never exposed before cure methods for MS. Levin says ...
 Town Hall1 week ago
Pharma Letter

NICE updates guidance for management of multiple sclerosis but does not recommend Bayer's Sativex

The UK's National Institute for Health and Care Excellence (NICE) has updated its guidance for the NHS management of multiple sclerosis. At present, people with MS can be left for more than a year with no monitoring of their condition or ...
 Pharma Letter1 week ago NICE rejects use of GW Pharmaceuticals' Sativex in multiple sclerosis  FirstWord Pharma1 week ago New Summary: Alemtuzumab for treating relapsingremitting multiple sclerosis. [National Institute for Health and Care Excellence (NICE)]  National Guideline Clearinghouse2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less